Drug Profile
KR 10664
Alternative Names: DA 1064Latest Information Update: 24 May 2001
Price :
$50
*
At a glance
- Originator Korea Research Institute of Chemical Technology
- Developer Dong-A Pharmaceutical; Korea Research Institute of Chemical Technology
- Class Antibacterials
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 24 May 2001 Discontinued-Preclinical for Bacterial infections in South Korea (Unknown route)
- 24 Aug 1998 Suspended-Preclinical for Bacterial infections in South Korea (Unknown route)
- 04 Oct 1995 Preclinical development for Bacterial infections in South Korea (Unknown route)